Antidiabetic Drugs and Parkinson’s Risk: What a Nine-Cohort Meta-Analysis Found
antidiabetic drugs Parkinson's risk: Antidiabetic drugs and Parkinson's risk were compared across nine observational cohorts totaling 712,287 patients. No class difference was statistically significant, although GLP-1 and SGLT2 therapies had favorable…
Semaglutide and Cognition in Psychiatric Care: What a 13,007-Patient Cohort Found
semaglutide cognition psychiatric cohort: In a retrospective cohort of 13,007 adults with psychiatric diagnoses, semaglutide initiation was associated with fewer clinician-recorded cognitive signs over 12 months than no antidiabetic treatment, glipizide,…
GLP-1 Drugs and Intracranial Hypertension: What a Low-Certainty Meta-Analysis Found
GLP-1 idiopathic intracranial hypertension evidence was synthesized across eight studies and 13,243 patients. Papilledema, headache, visual, and refractory-disease outcomes favored GLP-1 exposure. Observational dominance, confounding, and heterogeneity…
GLP-1 Plus SGLT2 Therapy: What an Exploratory Cardiorenal Meta-Analysis Found
GLP-1 SGLT2 combination cardiorenal outcomes were examined across 16 randomized trial datasets. Combination use ranked favorably for cardiovascular and kidney outcomes. The mostly nonrandomized subgroup comparisons make the findings hypothesis-generating…
Dulaglutide vs Insulin in Adolescents With Thalassaemia-Related Diabetes
dulaglutide thalassaemia diabetes trial: In an open-label randomized trial of 80 adolescents with transfusion-dependent beta-thalassaemia and diabetes, weekly dulaglutide improved glucose variability and several metabolic measures more than basal-bolus…
Once-Weekly IcoSema for Type 2 Diabetes: What COMBINE 4 Found
IcoSema COMBINE 4 trial: Once-weekly IcoSema lowered HbA1c and produced a more favorable body-weight change than daily insulin glargine over 40 weeks. Clinically significant or severe hypoglycemia was less frequent, while gastrointestinal disorders were…
Oral Semaglutide for Alcohol Use Disorder: What a New Randomized Trial Found
A phase 2 oral semaglutide alcohol use disorder randomized trial tested 50 adults with moderate to severe alcohol use disorder. The primary craving endpoint was not significantly improved, but several secondary drinking outcomes favored semaglutide.…
Oral VCT220 Phase II Trial: GLP-1 Receptor Agonist for Obesity
A 16-week phase II oral nonpeptide GLP-1 receptor agonist obesity trial found oral VCT220 produced significantly greater weight loss than placebo in 250 adults. The study showed mainly mild to moderate gastrointestinal adverse events but was limited by…
GLP-1 Medications May Quiet the Craving Behind Addiction
A landmark BMJ study published June 3, 2026 found that GLP-1 receptor agonists like semaglutide significantly reduced both the development and severity of substance use disorders in over 600,000 U.S. veterans. Cannabis use disorder risk dropped 14%,…
The No-Hunger Games- How GLP-1 Medication Adoption Is Changing Consumer Food Dem
GLP-1 medications lead to significant reductions in grocery spending, particularly in calorie-dense foods. This impact persists during medication use but reverses upon discontinuation.